Anti-cancer star drug opens breakout race 10 billion target stakes ushered in harvest period

The textEvayesterday, Baiji Shenzhou released its 2020Q1 results report, as of March 31, 2020, the company's revenue of $52.06 million, its Baize an since the commercial launch in China in March 2020, the product revenue of $20.53 millionthat's the PD-1 (Forrelli Pearl Single Resistance) sold for $20.53 million a monthPD-1 monoantigen as a broad-spectrum anti-cancer drug, once again let people see its future unlimited market potentialAccording to Frost Sullivan's estimates, the global PD1/PDL1 drug market could reach $78.9 billion in 2030 and China $13.1 billionat present, China approved a total of 6 PD-1 products, import PD-1 indications advantages are obvious, MersaDong K drug approved 4 indications and concentrated in China's high-risk type of lung cancer field, 3 first-line treatment drugs to make it in the treatment of non-small cell lung cancer has an absolute advantageBMS's O-drug approved three indications, two of which are the only in the countryAnd the domestic PD-1 indications are currently concentrated in the second and third lines, the specific situation is as follows:but from the CDE dynamic, the domestic PD-1 has entered the era of competition for large cancer indications, major enterprises product intensive approval and re-declaration of productionIn March, Henri PD-1 (Carrelli Pearl monoantigen) was approved for second-line treatment of liver cancerApril Baiji Shenzhou PD-1 (Tyreli Zhu mono-resistance) was approved for urinary disease, and its first-line treatment of NSCLC indications was also reported this month;May Junshi PD-1 (Treprimono resistance) and applied for urinary disease, Cinda PD-1 (Sindili monoantigen) first-line NSCLC phase III clinical reached the main end, will also be reported in the near futurein addition, its PD-1 in lung cancer, stomach cancer, liver cancer and other large cancer strains in a number of trials have been in the 3stage, so, although domestic PD-1 adaptation is not as important as imported, but also will usher in intensive harvest period, domestic PD-1 will usher in the stage of rapid growth of performancealso, from the price point of view, the domestic PD-1 is half lower than imports, the domestic competitive price advantage is obviousAfter THE PAP (Drug Assistance Program), the annual cost of treatment of "K medicine" in Mersadong reached about 3225 million yuan, and BMS's "O drug" was also as high as 2224 million yuanIn contrast, the annual cost of treatment for 4 domestic PD-1 mono-resistant patients is 10-12 million, which is about 50% cheaper than imported products In addition, in November 2019, Cinda PD-1 (Sindili mono-resistance) exclusive access to the national health insurance directory, the annual cost of treatment of patients fell to about 100,000 yuan indications and price war, PD-1 single resistance first echelon competition has begun, followed by a large number of pharmaceutical companies competing for research and development declaration, before and after the state of the clamping, the strategic pace of each enterprise has been urgent.
.. Time is money, early one step on the market to benefit patients, seize the market Junshi's PD-1 (Triprei monoantigen) melanoma indications, is through the priority review and the Phase II key clinical trial data declaration was conditionally approved for rapid listing, the first year of 2019 listing sales reached 774 million yuan Hengrui PD-1 (Carrelli Pearl Monoantigen) of liver cancer second-line, non-small cell lung cancer first-line and esophageal cancer second-line indications application for listing have also obtained priority review qualifications expensive patented drugs into the national health insurance catalog, first of all, can significantly reduce the patient's out-of-pocket costs, improve drug accessibility; for example, Cinda PD-1 (Sindili single anti-injection), in February 2019 landed in the domestic market, retail price of 7838 yuan / 100mg, after the "3 plus 2" PAP, the annual treatment cost of about 188,000 yuan In November 2019, exclusive access to the national health insurance directory, the payment price of medical insurance is 2843 yuan / branch (2 / 21 days / course of treatment), valid for two years, the annual cost of treatment of patients fell to about 100,000 yuan, medical insurance reimbursement after the annual cost of personal treatment of 3-4 million yuan Before entering health insurance, its 2019 full-year sales of 1.05 billion yuan, after the medical insurance 2020Q1 only by cHL an indication, sales growth of 400 million yuan, and with cHL indications of Hengrui and Baiji Shenzhou PD-1 single resistance approved late, missed a wave of opportunities clinical treatment preferred first-line drug, then second-line, third-line, so first-line indications can benefit patients more, more clinical value For example, Mercado's K-drug, after being approved for the first line of three non-small cell lung cancer indications, Q2 surpassed BMS's O drug in 2018, with record quarterly sales of $3.07 billion in 2019Q3, while BMS's O drug remained at $1.8 billion as far as domestic pharmaceutical companies are concerned, Hengrui PD-1 has been approved for second-line treatment of liver cancer indications, and many of the first-line treatment of large cancers have been in the second and third stages, looking forward to this year's outbreak finally, the pharmaceutical companies in accelerating the progress of research and development, expand the sales force, etc have their own strategic deployment, but also pharmaceutical companies have a global perspective, such as Hengrui recently for 87.75 million U.S dollars to its PD-1 project license to CG company, the next market, the wind surge, wait for more explosive spots, look forward to more patients to benefit ...